![conference banner](/images/conference-banner.jpeg)
Abstract
Vascular smooth muscle cells (VSMCs) contraction can be evoked by the rise of cytosolic [Ca2+] owing to transmembrane Ca2+ influx or sarcoplasmic reticulum (SR) Ca2+ release. Although the classical ionotropic role of voltagedependent (L-type) Ca2+ channels (VGCCs) is known, we review here data suggesting a new metabotropic function of VGCCs in vascular smooth muscle cells. VGCCs can trigger Ca2+ release from the SR in the absence of extracellular Ca2+. During depolarization, VGCCs can activate G proteins and phospholipase C (PLC)/inositol 1,4,5-trisphosphate (InsP3) pathway leading to Ca2+ release and arterial contraction. This new metabotropic role of VGCCs, referred as calcium channel-induced Ca2+ release (CCICR), has a major role in tonic VSM contractility, as it links sustained membrane depolarization and Ca2+ channel activation with metabotropic Ca2+ release from the sarcoplasmic reticulum (SR) and tonic smooth muscle contraction. This new role of VGCCs could have a wide functional relevance for the pathogenesis of vasospasms mediated by membrane depolarization and vasoactive agents that can activate VGCCs. Precise understanding of CCICR could help to optimize pharmacological treatments for clinical conditions where Ca2+ channels antagonists are recommended.
Keywords: Vascular smooth muscle, L-type Ca2+ channels, sarcoplasmic reticulum, depolarization-induced Ca2+ release, arterial contraction.
Current Vascular Pharmacology
Title:A New Metabotropic Role for L-type Ca2+ Channels in Vascular Smooth Muscle Contraction
Volume: 11 Issue: 4
Author(s): Juan Urena, Miguel Fernandez-Tenorio, Cristina Porras-Gonzalez, Patricia Gonzalez-Rodriguez, Antonio Castellano and Jose Lopez-Barneo
Affiliation:
Keywords: Vascular smooth muscle, L-type Ca2+ channels, sarcoplasmic reticulum, depolarization-induced Ca2+ release, arterial contraction.
Abstract: Vascular smooth muscle cells (VSMCs) contraction can be evoked by the rise of cytosolic [Ca2+] owing to transmembrane Ca2+ influx or sarcoplasmic reticulum (SR) Ca2+ release. Although the classical ionotropic role of voltagedependent (L-type) Ca2+ channels (VGCCs) is known, we review here data suggesting a new metabotropic function of VGCCs in vascular smooth muscle cells. VGCCs can trigger Ca2+ release from the SR in the absence of extracellular Ca2+. During depolarization, VGCCs can activate G proteins and phospholipase C (PLC)/inositol 1,4,5-trisphosphate (InsP3) pathway leading to Ca2+ release and arterial contraction. This new metabotropic role of VGCCs, referred as calcium channel-induced Ca2+ release (CCICR), has a major role in tonic VSM contractility, as it links sustained membrane depolarization and Ca2+ channel activation with metabotropic Ca2+ release from the sarcoplasmic reticulum (SR) and tonic smooth muscle contraction. This new role of VGCCs could have a wide functional relevance for the pathogenesis of vasospasms mediated by membrane depolarization and vasoactive agents that can activate VGCCs. Precise understanding of CCICR could help to optimize pharmacological treatments for clinical conditions where Ca2+ channels antagonists are recommended.
Export Options
About this article
Cite this article as:
Urena Juan, Fernandez-Tenorio Miguel, Porras-Gonzalez Cristina, Gonzalez-Rodriguez Patricia, Castellano Antonio and Lopez-Barneo Jose, A New Metabotropic Role for L-type Ca2+ Channels in Vascular Smooth Muscle Contraction, Current Vascular Pharmacology 2013; 11 (4) . https://dx.doi.org/10.2174/1570161111311040012
DOI https://dx.doi.org/10.2174/1570161111311040012 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Markers of Early Vascular Ageing
Current Pharmaceutical Design New Developments in Oral Vaccines and Mucosal Adjuvants
Recent Patents on Inflammation & Allergy Drug Discovery Anthocyanins: Plant Pigments, Food Ingredients or Therapeutic Agents for the CNS? A Mini-Review Focused on Clinical Trials
Current Pharmaceutical Design Treating Heart Failure with Preserved Ejection Fraction Related to Arterial Stiffness. Can we Kill Two Birds With One Stone?
Current Vascular Pharmacology Challenges and Controversies in Autoantibodies Associated with Systemic Rheumatic Diseases
Current Rheumatology Reviews Determination of the Sodium Concentration in Brazilian Light and Non- Light Powdered Instant Soups by Flame Photometry
Current Nutrition & Food Science Averrhoa bilimbi L. leaf Aqueous Extract Modulates both Cardiac Contractility and Frequency in the Guinea-pig Atrium by the Activation of Muscarinic Receptors
Letters in Drug Design & Discovery Allopurinol and Loss of Consciousness in a 78-old Year Man Suffering from Gout
Infectious Disorders - Drug Targets Nutraceutical: A Drug, Dietary Supplement and Food Ingredient
Current Pharmacogenomics and Personalized Medicine Disruption of Circadian Rhythms and Sleep in Critical Illness: Potential Implications for Angiogenesis After Myocardial Infarction. A Review
Current Pharmaceutical Design Omega-3 Fatty Acids: Role in Metabolism and Cardiovascular Disease
Current Pharmaceutical Design Pulmonary Arterial Hypertension (PAH) Group 1: Overview, Workup, Risk Stratification, and Current (and Future) Treatment Approaches
Current Respiratory Medicine Reviews The Cardiovascular Benefits of Caffeinated Beverages: Real or Surreal? “Metron Ariston - All in Moderation”
Current Medicinal Chemistry Development of Radiolabeled Compounds for Myocardial Perfusion Imaging
Current Pharmaceutical Design Editorial (Diabetes, Obesity and Vascular Disease - An Update)
Current Pharmaceutical Design Molecular Basis of Adrenomedullin 1 Receptor Function and Its Roles in the Cardiovascular System
Current Hypertension Reviews Resveratrol as a Gene Regulator in the Vasculature
Current Pharmaceutical Biotechnology Physical Exercise and Major Depressive Disorder - Where Do We Stand?
Current Psychopharmacology Rational Drug Design Paradigms: The Odyssey for Designing Better Drugs
Combinatorial Chemistry & High Throughput Screening Structural and Molecular Tear Film Changes in Glaucoma
Current Medicinal Chemistry